CGON Stock Forecast & Price Target

CG Oncology Inc. is positioned for significant growth as it prepares for a product launch of its candidate, cretostimogene grenadenorepvec, in 2026, with projected sales reaching approximately $2.6 billion by 2034. The company’s strong emphasis on the unique durability and efficacy of its therapeutic, combined with a keen strategy for addressing unmet needs in bladder cancer treatments, enhances its potential market appeal and physician adoption. Additionally, management's readiness for commercialization and the favorable regulatory trajectory further solidify the positive outlook for CG Oncology's future financial performance.

CG Oncology's negative outlook is primarily influenced by the competitive landscape in oncology, particularly highlighted by the collapse of Zaltrap against Avastin, suggesting that without distinguishing advantages, higher-priced therapeutics may struggle in securing reimbursement from payers. Additionally, potential risks arise from negative trial outcomes, slower enrollment, and adverse regulatory decisions, all of which could impede commercialization efforts and market potential, emphasizing the precarious nature of the company's future. Concerns about the robustness of intellectual property protection and effectiveness in the intermediate-risk NMIBC segment further exacerbate uncertainties surrounding CG Oncology's ability to achieve sustainable competitive advantage in the biopharmaceutical market.